Mid-Atlantic Bio
October 22 – 24
Chantilly, VA
Westfields Marriott Washington Dulles, 14750 Conference Center Drive, Chantilly, VA 20151 USA
The 2009 Mid-Atlantic Bio conference will bring together more than 850 national and international industry leaders, government representatives, executives, researchers, investors, entrepreneurs, and professional services firms—representing 30 states and 10 countries—in a unique forum to promote networking, business expansion, and technical-knowledge sharing.
This year, the conference will feature a Healthcare Policy Panel. Experts will arm conference attendees with insider information that will refine their organization’s strategic planning based on recent federal health reform legislation, continuing impacts from the current economic environment, and the opportunity to benefit from federal stimulus funds.
Testimonials
"Mid-Atlantic Bio has quickly gained recognition as a substantive, regionally hosted forum and a popular place for members of the local bioscience industry to gather…[a]long with numerous marketing and networking opportunities."
"The Mid-Atlantic region is lucky to have what has quickly become recognized as one of the best local conferences…Mid-Atlantic Bio."
Frederick News-Post
2009 Keynote Speakers
For the 2009 Mid-Atlantic Bio Conference, keynote speaker Randal Kirk, Senior Managing Director and CEO of Third Security, will provide insights on innovations and advances within the industry. More information on the keynote speakers may be found here.
Keynote speakers
Mid-Atlantic Bio consistently attracts the best and the brightest keynote speakers within the biotech field. You can expect this year's conference to live up to this tradition.
2008 Plenary speakers to include:
 | Stuart Rothenberg
Editor and Publisher, The Rothenberg Political Report,
And Columnist, Roll Call |
News
Baltimore-Based CSA Medical Raises $20.5 Million in Second Round
Baltimore — CSA Medical, the Baltimore-based developer of a spray cryotherapy device that freeze and destroy unwanted tissue inside the body, said on Thursday it has raised $20.5 million in its second round of funding, co-led by Intersouth Partners and First Analysis. Other investors in the round included S.V. Life Sciences, Rose Park, and Blue Heron Capital. The company will use the proceeds to fund post-market clinical studies and ongoing development activities. “This partnership and funding will support the launch of our new platform, expanded utilization and further development of new clinical applications,” said CEO Bill Floyd. CSA’s technology is currently being used at more than 80 cancer centers and academic teaching hospitals to treat esophageal disease.
http://www.csamedical.com
http://www.businesswire.com/news/home/20111215005360/en/CSA-Medical%E2%84%A2-Completes-20.5-Million-Series-Financing
Baltimore-Based CSA Medical Raises $12.6 Million in First Round
Baltimore — CSA Medical, a Baltimore-based developer of devices that flash freeze and treat diseased tissue inside the body, said on Tuesday it has raised $12.6 million in its first round of funding, which included a new investment from Blue Heron Capital. The company, which said it already is in discussions with investors about a potential second round, plans to use the proceeds to support the launch of its technology platform. The technology, which uses an endoscopic tool to spray extreme cold liquid nitrogen, is currently being used to treat esophageal disease at nearly 80 U.S. cancer centers and academic teaching hospitals.
http://www.csamedical.com
http://www.prnewswire.com/news-releases/csa-medical-completes-126-million-series-a-financing-with-additional-venture-investment-from-blue-heron-capital-125410798.html
Rockville-Based Supernus Raises $42 Million to Prepare Drugs for Launch
Rockville, Md. — Supernus Pharmaceuticals, a Rockville-based specialty pharmaceutical firm developing treatments for disorders of the central nervous system, said on Friday it has raised $42 million through a pair of transactions. The company said it generated $27 million from the sale of its TCD Royalty unit, as well as another $15 million from the issuance of venture debt. Supernus said it will use the proceeds to prepare for the commercial launch of its two lead product candidates in epilepsy, as well as to further develop its pipeline. “We have been able to raise more than $165 million through a series of five non-dilutive financing,” said Jack Khattar, the company’s president and CEO.
http://www.supernus.com
http://www.businesswire.com/news/home/20120106005025/en/Supernus-Pharmaceuticals-Raises-42-Million-Prepare-Launch
